Figure 1. Guanylyl cyclase (GC) pathways, activation of cGMP as their second messenger
Figure 2CD-NP
Coresh J , Astor B , Sarnak MJ . Evidence for increased cardiovascular disease risk in patients with chronic kidney disease. 2004; 13:73–81.
Culleton, BF , et al.. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. 1999; 56:2214–2219.
Dries DL , et al.. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000; 35:681–689.
Garg, AX , et al.. Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. Kidney Int 2002; 61:1486–1494.
Go AS , et al.. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296–1305.
Henry RM , et al.. Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int 2002; 62:1402–1407.
van Dokkum RP , et al.. Myocardial infarction enhances progressive renal damage in an experimental model for cardio-renal interaction. J Am Soc Nephrol 2004; 15:3103–3110.
Doty JM , et al.. Effect of increased renal venous pressure on renal function. 1999; 4:1000–1003.
Malbrain ML , et al.. Results from the International Conference of Experts on Intra-abdominal Hypertension and Abdominal Compartment Syndrome. I. Definitions. Intensive Care Med 2006; 32:1722–32.
Damman K , et al.. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol 2009; 53:582–8.
Schlaich MP , et al.. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009; 361:932–4.
St John Sutton M , et al.. Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial. Circulation 1997; 96:3294–9.
Vaziri ND , et al.. Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency. Kidney Int 2003; 63:179–85.
Martin FL , et al.. B-type natriuretic peptide: beyond a diagnostic. Heart Fail Clin 2008; 4:449–54.
Boerrigter G , Lapp H , Burnett JC . Modulation of cGMP in heart failure: a new therapeutic paradigm. Handb Exp Pharmacol 2009; 191:485–506.
Cataliotti A , et al.. Natriuretic peptides as regulators of myocardial structure and function: pathophysiologic and therapeutic implications. Heart Fail Clin 2006; 2:269–76.
Mohammed SF , et al.. Nesiritide in acute decompensated heart failure: current status and future perspectives. Rev Cardiovasc Med 2008; 9:151–8.
Lisy O , et al.. Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol 2008; 52:60–8.
Lee CY , et al.. Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects. J Clin Pharmacol 2009; 49:668–73.
McKie PM , Sangaralingham SJ , Burnett JC Jr . CD-NP: An Innovative Designer Natriuretic Peptide Activator of Particulate Guanylyl Cyclase Receptors for Cardiorenal Disease. Curr Heart Fail Rep 2010.
Rubattu S , et al.. Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases. Am J Hypertens 2008; 21:733–41.
Best PJ , et al.. Dendroaspis natriuretic peptide relaxes isolated human arteries and veins. Cardiovasc Res 2002; 55:375–84.
Pan S , et al.. Biodesign of a renal-protective peptide based on alternative splicing of B-type natriuretic peptide. Proc Natl Acad Sci USA, 2009; 106:11282–7.
Dickey DM , Burnett JC Jr. , Potter LR . Novel bifunctional natriuretic peptides as potential therapeutics. J Biol Chem 2008; 283:35003–9.